about
Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens.Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Adjuvant chemotherapy in 2005: standards and beyond.
@ast
Adjuvant chemotherapy in 2005: standards and beyond.
@en
type
label
Adjuvant chemotherapy in 2005: standards and beyond.
@ast
Adjuvant chemotherapy in 2005: standards and beyond.
@en
prefLabel
Adjuvant chemotherapy in 2005: standards and beyond.
@ast
Adjuvant chemotherapy in 2005: standards and beyond.
@en
P2093
P1433
P1476
Adjuvant chemotherapy in 2005: standards and beyond
@en
P2093
Bernard-Marty Ch
Dal Lago L
Piccart MJ
de Valeriola D
P304
P356
10.1016/J.BREAST.2005.08.004
P577
2005-09-26T00:00:00Z